Eiger Biopharmaceuticals (NASDAQ:EIGR) had its price objective boosted by research analysts at Piper Jaffray to $28.00 in a research report issued to clients and investors on Friday. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Piper Jaffray’s price objective would suggest a potential upside of 66.67% from the company’s current price.
EIGR has been the subject of a number of other research reports. BTIG Research increased their target price on shares of Eiger Biopharmaceuticals from $23.00 to $39.00 and gave the stock a “buy” rating in a research report on Thursday. Oppenheimer reiterated a “buy” rating on shares of Eiger Biopharmaceuticals in a research report on Wednesday, March 21st. Wedbush dropped their target price on shares of Eiger Biopharmaceuticals from $36.00 to $34.00 and set an “outperform” rating for the company in a research report on Thursday, March 22nd. ValuEngine upgraded shares of Eiger Biopharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, April 13th. Finally, Zacks Investment Research upgraded shares of Eiger Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research report on Tuesday. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $29.00.
Shares of Eiger Biopharmaceuticals opened at $16.80 on Friday, Marketbeat reports. The stock has a market cap of $124.90 million, a P/E ratio of -3.46 and a beta of 1.60. The company has a quick ratio of 5.85, a current ratio of 4.51 and a debt-to-equity ratio of 0.81. Eiger Biopharmaceuticals has a 12-month low of $11.35 and a 12-month high of $11.90.
Eiger Biopharmaceuticals (NASDAQ:EIGR) last announced its earnings results on Friday, May 11th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.96) by $0.12. equities research analysts forecast that Eiger Biopharmaceuticals will post -3.71 EPS for the current fiscal year.
In other Eiger Biopharmaceuticals news, insider Joanne Quan sold 4,000 shares of the firm’s stock in a transaction dated Monday, April 2nd. The shares were sold at an average price of $10.00, for a total value of $40,000.00. Following the completion of the sale, the insider now owns 4,000 shares in the company, valued at approximately $40,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 7.90% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of EIGR. JPMorgan Chase & Co. increased its position in Eiger Biopharmaceuticals by 295.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 11,705 shares of the biotechnology company’s stock valued at $126,000 after acquiring an additional 8,748 shares in the last quarter. Jennison Associates LLC acquired a new stake in Eiger Biopharmaceuticals in the 4th quarter valued at about $8,430,000. P.A.W. Capital Corp increased its position in Eiger Biopharmaceuticals by 25.0% in the 4th quarter. P.A.W. Capital Corp now owns 100,000 shares of the biotechnology company’s stock valued at $1,395,000 after acquiring an additional 20,000 shares in the last quarter. Unterberg Capital LLC bought a new position in shares of Eiger Biopharmaceuticals in the 4th quarter valued at about $698,000. Finally, Prosight Management LP bought a new position in shares of Eiger Biopharmaceuticals in the 4th quarter valued at about $9,469,000. Hedge funds and other institutional investors own 70.33% of the company’s stock.
Eiger Biopharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.